Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS): A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Trials

Next Previous
X
Search
Trial Profile

Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS): A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Trials

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Perampanel (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use

    • Most Recent Events

    • 01 Feb 2022 Results assessing efficacy and safety of perampanel in patients with sporadic amyotrophic lateral sclerosis published in the Journal of Neurology
    • 14 Jan 2021 Status changed from active, no longer recruiting to completed.
    • 01 May 2020 Results assessing safety and the efficacy of perampanel in patients with sporadic amyotrophic lateral sclerosis, presented at the 72nd Annual Meeting of the American Academy of Neurology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top